




A monthly report summarizing the Life Science transactions and trends in Washington State.


Washington State Transactions

Washington State Transactions by Sector



Number of Deals per Sector

*As of 11/30/20



Monthly Highlights

HIGHLIGHTS

- **Umoja Biopharma**, a biotechnology company pioneering an integrated in vivo immunotherapy platform, announced completion of its \$53 million Series A fundraising. Umoja’s suite of innovations will re-engineer a patient’s own immune system to attack and destroy both hematologic and solid organ-based tumors with a simplicity and cost that enables widespread implementation. ([Geekwire](#); [Company website](#))
- **Silverback Therapeutics** filed for an IPO. Silverback uses a proprietary platform called ImmunoTAC to develop therapies that target specific areas of disease in a way that avoids damaging healthy tissue. The lead product candidate SBT6050 is currently in Phase 1/1b clinical trials. ([Company website](#); [Geekwire](#))
- **Frazier Healthcare Partners** filed with the Securities and Exchange Commission to raise \$100M for a special purpose acquisition corporation (SPAC). Frazier’s SPAC will be the **Frazier Lifescience Acquisition Corporation (FLAC)** and will be led by key members of the Frazier Healthcare team. FLAC plans to invest in biotechnology with a company can “both develop transformative therapies for patients in need and deliver significant returns to its investors.” ([Frazier Healthcare Partners](#))

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.



Washington Life Science Transactions

Date	Company	Type	Amount	Date	Company	Type	Amount
1/20/2020	Optimize.health	Equity	\$3,500,000	6/2/2020	eDoula	Convertible Debt	\$50,000
1/23/2020	Athira Pharma	Convertible Debt	\$3,830,000	6/3/2020	AIDA Healthcare	Convertible Debt	\$515,000
1/29/2020	Ventec Life Systems	Equity	\$24,030,000	6/4/2020	Kineta	Equity	\$100,000
1/31/2020	Twistle	Equity	\$18,000,000	6/4/2020	Athira Pharma	Cash	\$85,500,000
1/31/2020	Soovu Labs	Convertible Debt	\$800,000	6/11/2020	Sana Biotechnology	Cash	\$435,000,000
2/1/2020	ActX	Cash	\$5,900,000	6/12/2020	MicrobiomX	Convertible Debt	\$505,000
2/1/2020	Inmedix	ven	undisclosed	6/17/2020	Proprio	Cash	\$23,000,000
2/1/2020	Proteios Technology	Cash	undisclosed	6/22/2020	Oisin	Equity	\$5,090,000
2/11/2020	Cardiac Insight	Debt	\$8,000,000		Biotechnologies		
2/14/2020	Bardy Diagnostics	Cash	\$12,490,000	6/24/2020	Modento	Equity	\$1,000,000
2/18/2020	PharmID	Equity	\$5,000,000	7/8/2020	LumniThera	Cash	\$14,000,000
2/19/2020	CuraCloud	Cash	undisclosed	7/13/2020	Ulcer Solutions	Equity	undisclosed
2/20/2020	Lupa Bio	Convertible Debt	undisclosed	7/13/2020	Innovega	Equity	\$2,140,000
2/21/2020	AVM Biotechnology	Equity	\$2,570,000	7/21/2020	Curvafix	Equity	\$10,750,000
2/24/2020	Selkirk Pharma	Equity	\$9,050,000	7/22/2020	Magnolia	Equity	\$5,000,000
2/25/2020	Oisin Biotechnologies	Equity	\$2,970,000		Neurosciences		
2/26/2020	PVP Biologics		\$3,300,000	8/4/2020	Proprio	Equity	\$220,000
2/27/2020	WellPepper	Equity	undisclosed	8/6/2020	Xealth	Equity	\$6,000,000
2/28/2020	Pacific Rim Outpatient Surgery Center		undisclosed	8/10/2020	Variant Bio	Equity	\$8,100,000
3/1/2020	Joylux	Cash	undisclosed	8/13/2020	Aminex	Convertible Debt	\$2,870,000
3/1/2020	LumniThera	Cash & Equity	undisclosed		Therapeutics		
3/1/2020	Nanodropper	Cash	\$30,000	8/20/2020	Optimize.health	Equity	\$15,000,000
3/11/2020	Silverback	Equity	\$78,500,000	8/25/2020	Prescriptive	Equity	\$26,000,000
	Therapeutics				Deverra		
3/11/2020	OtoNexus Medical	Equity	\$9,700,000	8/27/2020	Therapeutics	Equity	\$80,000
	Technologies			9/1/2020	Lumen Bioscience	Equity	\$16,000,000
3/19/2020	Concure Oncology	Cash & Equity	\$7,750,000	9/14/2020	Implicit Bioscience	Equity	\$65,551
3/20/2020	Medcurity	Cash & Equity	\$737,500	9/17/2020	Cyrus Biotechnology	Convertible Debt	\$1,130,000
3/26/2020	Novuson Surgical	Cash & Equity	\$2,380,000	9/18/2020	Athira Pharma	IPO	\$204,000,000
4/1/2020	YouScript	M&A	\$79,300,000	9/23/2020	Silverback	Equity	\$85,000,000
4/1/2020	Sentinel Healthcare		undisclosed		Therapeutics		
4/1/2020	SCI Solutions	Cash	\$190,000,000	9/25/2020	Immusoft	Equity	\$4,500,000
4/2/2020	Blaze Bioscience	Cash & Equity	\$23,230,000	9/25/2020	Altpep	Equity	\$2,100,000
4/2/2020	Rodeo Therapeutics	Equity	\$8,950,000	9/27/2020	Inmedix	Debt and Equity	\$3,500,000
4/3/2020	98point6	Cash	\$43,000,000	9/28/2020	ImvaqTherapeutics	Equity	\$15,000,000
4/6/2020	Juva for Migraine		\$500,000	9/28/2020	Cardiac Dimensions	Equity	\$17,500,000
4/15/2020	SiDx	Convertible Debt	\$1,250,000	9/29/2020	TourniTek	Equity	\$10,265
4/21/2020	welcomhomehealth.com	Equity	\$1,500,000	10/5/2020	HDT Bio	Equity	\$3,000,000
4/22/2020	Myosana	Cash	\$1,000,000	10/13/2020	Genemod	Equity	\$1,700,000
	Therapeutics			10/15/2020	98point6	Equity	\$118,690,000
4/26/2020	Avalyn	Cash	\$35,500,000	10/29/2020	Concure Oncology	Equity	\$9,750,000
5/5/2020	Kineta	Equity	\$5,000,000	11/10/2020	Arzeda	Convertible Debt	\$4,250,000
5/18/2020	Nautilus	Cash	\$76,060,000	11/18/2020	Umoja Biopharma	Equity	\$53,000,000
	Biotechnology			11/20/2020	MicroMend	Convertible Debt	\$4,600,000
5/21/2020	Good Therapeutics	Cash	\$22,340,000				
5/22/2020	MDMetrix	Cash	\$1,150,000				
5/22/2020	Stratos Genomics		undisclosed				
5/22/2020	Tasso	Cash	\$17,000,000				
5/27/2020	Alvaxa Biosciences		undisclosed				
					Total		\$2,298,133,316

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.